Free tool
FAERS Monitor: Contepo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212271 or its brand name (Contepo, Fosfomycin Disodium). Reports on generic versions are filed under their own applications.
Reports
4
Serious
4
100% of reports
Hospitalization
4
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- acute kidney injury2
- ascites2
- chills2
- contusion2
- cystitis2
- dry mouth2
- fatigue2
- gastroenteritis2
- haematuria2
- lipase increased2
- liver function test increased2
- malignant neoplasm progression2
- nausea2
- oedema peripheral2
- pruritus2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lipase increased | 2 | 1372.9 | 515.1 | 1,542 |
| gastroenteritis | 2 | 720.4 | 270.3 | 808 |
| liver function test increased | 2 | 489.9 | 183.8 | 549 |
| ascites | 2 | 357.7 | 134.3 | 400 |
| cystitis | 2 | 330.2 | 123.9 | 369 |
| haematuria | 2 | 307.1 | 115.3 | 343 |
| dry mouth | 2 | 129.6 | 48.6 | 143 |
| contusion | 2 | 109.2 | 41.0 | 120 |
| malignant neoplasm progression | 2 | 102.7 | 38.5 | 113 |
| chills | 2 | 89.7 | 33.7 | 98 |
| oedema peripheral | 2 | 86.3 | 32.4 | 95 |
| acute kidney injury | 2 | 68.7 | 25.8 | 75 |
| pruritus | 2 | 27.4 | 10.3 | 28 |
| fatigue | 2 | 13.5 | 5.1 | 13 |
| nausea | 2 | 13.3 | 5.0 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.